News Releases

With CAR T cell therapy, a patient’s own immune cells are genetically modified and inserted back into the body to find and kill cancer. This form of immunotherapy has already revolutionized some cancer treatments, but once the CAR T cells are inside a patient, where do they go? How do doctors know that they have successfully reached their target and that they are continuing to fight disease weeks, months, or even years later?

Knowing which T cells will lose the battle against cancer earlier could inform treatments and the development of new immunotherapies

A new $3 million grant to support a clinical trial evaluating a combination therapy to prevent triple-negative breast cancer from recurring will be led in the clinic by Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence in the Abramson Cancer Center (ACC) at the University of Pennsylvania and co-director of the ACC’s 2-PREVENT Translational Center of Excellence.